Editorial: Chemistry: A key science to fight neglected diseases/Química: Ciência central para combater doenças negligenciadas

Over the past century, chemical and pharmaceutical industries have made substantial strides in the development of new pharmaceuticals for a range of human diseases. Discovering and developing new drugs are part of a costly process that involves not only the search for new drug candidates, but also t...

Full description

Bibliographic Details
Main Authors: Adilson Beatriz, Dênis Pires de Lima
Format: Article
Language:English
Published: Universidade Federal de Mato Grosso do Sul 2009-12-01
Series:Orbital: The Electronic Journal of Chemistry
Subjects:
Online Access:http://www.orbital.ufms.br/index.php/dqi/article/view/118/33
id doaj-863f486214f14db3ac497a5cfcc4f192
record_format Article
spelling doaj-863f486214f14db3ac497a5cfcc4f1922020-11-25T01:36:41ZengUniversidade Federal de Mato Grosso do SulOrbital: The Electronic Journal of Chemistry1984-64282009-12-0114Editorial: Chemistry: A key science to fight neglected diseases/Química: Ciência central para combater doenças negligenciadasAdilson BeatrizDênis Pires de LimaOver the past century, chemical and pharmaceutical industries have made substantial strides in the development of new pharmaceuticals for a range of human diseases. Discovering and developing new drugs are part of a costly process that involves not only the search for new drug candidates, but also the performance of clinical trials. It is not uncommon to find reports of costs reaching US$ 500 million—and even US$ 1 billion—engaging multidisciplinary teams for periods of 10 or 15 years. To a large extent, these costs are borne by consumers in richer countries. In contrast, diseases that predominantly affect residents of poorer nations tend to be left out of the modern process of drug discovery. Moreover, most of the world population stricken by these illnesses is incapable of supporting the costs involved in developing the drugs they need. Because these infirmities, with few exceptions, have been ignored by those in charge of research programs, both in the public and private sectors, they have been referred to as neglected diseases. On its website, the World Health Organization categorizes 14 health conditions as “tropical diseases,”.......................http://www.orbital.ufms.br/index.php/dqi/article/view/118/33editorialorbitalneglected diseases
collection DOAJ
language English
format Article
sources DOAJ
author Adilson Beatriz
Dênis Pires de Lima
spellingShingle Adilson Beatriz
Dênis Pires de Lima
Editorial: Chemistry: A key science to fight neglected diseases/Química: Ciência central para combater doenças negligenciadas
Orbital: The Electronic Journal of Chemistry
editorial
orbital
neglected diseases
author_facet Adilson Beatriz
Dênis Pires de Lima
author_sort Adilson Beatriz
title Editorial: Chemistry: A key science to fight neglected diseases/Química: Ciência central para combater doenças negligenciadas
title_short Editorial: Chemistry: A key science to fight neglected diseases/Química: Ciência central para combater doenças negligenciadas
title_full Editorial: Chemistry: A key science to fight neglected diseases/Química: Ciência central para combater doenças negligenciadas
title_fullStr Editorial: Chemistry: A key science to fight neglected diseases/Química: Ciência central para combater doenças negligenciadas
title_full_unstemmed Editorial: Chemistry: A key science to fight neglected diseases/Química: Ciência central para combater doenças negligenciadas
title_sort editorial: chemistry: a key science to fight neglected diseases/química: ciência central para combater doenças negligenciadas
publisher Universidade Federal de Mato Grosso do Sul
series Orbital: The Electronic Journal of Chemistry
issn 1984-6428
publishDate 2009-12-01
description Over the past century, chemical and pharmaceutical industries have made substantial strides in the development of new pharmaceuticals for a range of human diseases. Discovering and developing new drugs are part of a costly process that involves not only the search for new drug candidates, but also the performance of clinical trials. It is not uncommon to find reports of costs reaching US$ 500 million—and even US$ 1 billion—engaging multidisciplinary teams for periods of 10 or 15 years. To a large extent, these costs are borne by consumers in richer countries. In contrast, diseases that predominantly affect residents of poorer nations tend to be left out of the modern process of drug discovery. Moreover, most of the world population stricken by these illnesses is incapable of supporting the costs involved in developing the drugs they need. Because these infirmities, with few exceptions, have been ignored by those in charge of research programs, both in the public and private sectors, they have been referred to as neglected diseases. On its website, the World Health Organization categorizes 14 health conditions as “tropical diseases,”.......................
topic editorial
orbital
neglected diseases
url http://www.orbital.ufms.br/index.php/dqi/article/view/118/33
work_keys_str_mv AT adilsonbeatriz editorialchemistryakeysciencetofightneglecteddiseasesquimicacienciacentralparacombaterdoencasnegligenciadas
AT denispiresdelima editorialchemistryakeysciencetofightneglecteddiseasesquimicacienciacentralparacombaterdoencasnegligenciadas
_version_ 1725061562282016768